INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10603429
Filing Date		2003-06-24
First Named Inventor	Zifei	Wang
Art Unit		3762
Examiner Name	Mich	ael W. Kahelin
Attorney Docket Numb	er	A03P1031

			PATENTS	Remove		
Examiner   Cite   Patent Number   Kind   Code1		Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	3828768		1974-08-13	Douglas	
	2	4674509		1987-06-23 DeCote, Jr.		
	3	4679144	79144 1987-07-07		Cox et al.	
	4	4799486		1989-01-24	DuFault	
	5	4974162		1990-11-27	Siegel et al.	
	6	5159932		1992-11-03	Zanetti et al.	
	7	5199428		1993-04-06	Obel et al.	
	8	5213106		1993-05-25	Lerner	

		Application Number		10603429		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Filing Date		2003-06-24		
		First Named Inventor	First Named Inventor Zifei W		Wang	
		Art Unit		3762		
		Examiner Name Mich		ael W. Kahelin		
		Attorney Docket Numb	er	A03P1031		

9	5365426		1994-11-15 Siegel et al.		
10	5531768		1996-07-02	Alferness	
11	5560368		1996-10-01	Berger	
12	5978710		1999-11-02	Prutchi et al.	
13	6155267		2000-12-05	Nelson	
14	6361503	B1	2002-03-26	Starobin et al.	
15	6539259	B1	2003-03-25	Weinberg et al.	
16	6604000	B2	2003-08-05	Lu	
17	6609023	B1	2003-08-19	Fischell et al.	
18	6823213	B1	2004-11-23	Norris et al.	
19	5792065		1998-08-11	Xue et al.	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

If you wish to add additional U.S. Patent citation information please click the Add button.

	Application Number		10603429		
Filing Date			2003-06-24		
	First Named Inventor	Zifei Wang			
	Art Unit		3762		
	Examiner Name	Mich	ichael W. Kaheln		
Attorney Docket Number		er	A03P1031		

Add

Pages Columns Lines where

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Relev	ant Passages or Relevant as Appear
	1	20030073914	A1	2003-0	4-17	Taha et al.			
	2	20030144700	A1	2003-0	7-31	Brown et al.			
	3	20030153956	A1	2003-0	8-14	Park et al.			
	4	20030208129	A1	2003-1	1-06	Beker et al.			
	5	20040077941	A1	2004-0	4-22	Reddy et al.			
	6	20040249420	A1	2004-1	2-09	Olson et al.			
	7	20030060724	A1	2003-0	3-27	Thiagarajan el	tal.		
If you wish to add additional U.S. Published Application citation information please click the Add button. Add									
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

U.S.PATENT APPLICATION PUBLICATIONS

#### 

	1										
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner   Cite   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Τs		
	1										
If you wish to add additional non-patent literature document citation information please click the Add button Add											
	EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered										

See Kint Codes of USPTO Patent Documents at Invent/ISPTO.QDV or MPEP 901.04. Enter office that issued the document, by the Nov-letter option Standard ST3.) For Explanates petal or Lournets, the inclusion of the year of the region or preceded to ever an order to the patent document. A Standard ST3. For Explanates petal order to the patent document. If Not of Cocument by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Speciant is to place a check mark here if Explain language translation is attached.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10603429		
Filing Date		2003-06-24		
First Named Inventor	Zifei Wang			
Art Unit		3762		
Examiner Name	Micha	fichael W. Kahelm		
Attorney Docket Number		A03P1031		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 t	o make the	appropriate se	election(s):
---------------	----------	------------	------------	----------------	--------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

#### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David Sansky/	Date (YYYY-MM-DD)	2006-07-21
Name/Print	David Sarisky	Registration Number	41288

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.